ACG has acquired a significant stake in IQGEN-X, a Mumbai-based start-up contract research organization (CRO).
Supplier of integrated pharmaceutical manufacturing solutions, ACG, has revealed in a Nov. 3, 2020 press release, that it has acquired a significant stake in IQGEN-X, a Mumbai-based start-up contract research organization (CRO).
The investment supports ACG’s augmentation into R&D and intellectual property in drug development. Additionally, ACG’s funds into the start-up will be used to set up a current good practice manufacturing facility and the development and filling of abbreviated new drug applications (ANDAs).
“IQGEN-X’s excellent track record in patents and ANDAs speaks for itself, and we look forward to benefitting from its niche technology, broad-based expertise, and research specialization that has been recognized globally by WHO [World Health Organization] and the US FDA [Food and Drug Administration],” said Karan Singh, managing director, ACG, in the press release. “For ACG, this partnership will immediately help expand our group capabilities, and will accelerate our innovation strategy of bold, disciplined investment and world class execution to drive sustainable long-term growth with drug companies in India and global markets.”
Dr. Mandar M Kodgule, chairman and CEO, IQGEN-X commented, in the press release, “We at IQGEN-X are delighted to have ACG as partner whose strong global footprints and excellent operational capabilities, bring great synergy to IQGEN-X’s growth strategy. ACG's strategic investment augments our technical expertise, portfolio strategy, and corporate vision to create a robust portfolio of limited competition complex products for regulated markets. We believe that this partnership will open several other opportunities which will accelerate growth of both companies.”
Source: ACG
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.